Research-backed Botox methodology rooted in muscle physiology and mechanics for elevated results.
The ARCHITOX
Method
What is it?
ARCHITOX™ is a data-driven, advanced Botox application method designed to optimize neuromodulator outcomes through precise mapping of muscle bulk and surface area, ensuring maximum efficacy and longevity.
Engineered for an elevated aesthetic, ARCHITOX™ delivers maximum upper-face refinement, balanced brow dynamics, and progressive muscle bulk reduction. It follows research-backed dosing strategies aligned with the regulated 80-unit standard while adapting to individual anatomy for optimal results.
How is it different?
In contrast to traditional Botox application, which adheres to generalized dosing guidelines and injection patterns, ARCHITOX™ employs a precision-based methodology rooted in muscle physiology and mechanics. Unit allocation is determined through the analysis of muscle bulk and surface area—key variables that are not addressed in standard industry protocols.
This advanced approach achieves superior outcomes by not only reducing lines and etched wrinkles but also addressing dynamic imbalances in muscle movement. The result is a more refined, symmetrical appearance with long-term benefits, including improved treatment longevity and cumulative effects of muscle bulk reduction over time.
The ARCHITOX Advantage
Standardized, Predictable Outcomes – By calibrating dosage based on muscle bulk and contraction patterns, ARCHITOX™ eliminates variability, ensuring consistent neuromodulator effects and reducing patient anxiety related to uncertain results.
Optimized Treatment Longevity – The dose-response relationship is customized to individual muscle strength and surface area, prolonging clinical efficacy while minimizing premature metabolic breakdown.
Prevention of Macro-Compensation – Comprehensive mapping of the upper face prevents hyperactivity in untreated muscles, which can result in overcompensation and dysregulated movement patterns.
Prevention of Micro-Compensation – By addressing intra-muscular variability, ARCHITOX™ minimizes localized overactivity within a single muscle group, preventing subtle imbalances that contribute to unnatural facial dynamics.
Sustained Muscle Adaptation – Over time, strategic dosing reduces excessive muscle bulk while preserving functional integrity, leading to a refined yet physiologically balanced result in both male and female patients.
Supported by science
ARCHITOX™ customizes dosing to individual anatomy, sometimes exceeding the standard 80-unit guideline to achieve optimal results. By definition, treatments exceeding this threshold are considered “high dose.”
High-dose botulinum neurotoxin A (BoNTA) is emerging as a superior approach, with research suggesting that “high-dose” BoNTA may be the optimal dose and that “approved doses…are efficacious, [but] this does not mean they are optimal.” This insight, from High-Dose Neuromodulators: A Roundtable on Making Sense of the Data in Real-World Clinical Practice (Aesthetic Surgery Journal Open Forum, December 2021), supports innovative methods like ARCHITOX™ which refine high-dose applications to maximize efficacy.
Why analysis of muscle bulk and surface area is important
see below
Same dose? Not even close.
Due to significant variability between individuals, standard patterns and guidelines are ineffective—each muscle must be individually assessed to ensure optimal dosing based on
SIZE, STRENGTH, and MOVEMENT.
The above shows muscle compensation due to inadequate dosing.
Traditional dosing guidelines/patterns may reduce lines at rest, but facial movement is dynamic and unconscious. The only time your face is truly still is in a posed mirror reflection or selfie—this is not how you appear in real life.
An optimal Botox treatment must go beyond surface-level wrinkle reduction to ensure balanced muscle activity, preventing long-term issues such as hypertrophy in unintended areas and progressive compensation patterns that disrupt natural facial harmony.
This is why muscle bulk and surface area assessment are critical—precise dosing must account for individual anatomy to achieve both aesthetic and functional balance.
Elevating results for consumers and confidence for providers.
see below
Patient Story
Louise MCLoughlin, Age 37 - Urologist, Specializing in Uro-Oncology, Toronto CA
“There is no comparison between ARCHITOX™ and my previous experiences with Botox. The assessment was comprehensive and in-depth, the treatment areas were specifically marked out, and the rationale for the dose was clearly explained. The attention to detail throughout the assessment and application was incredible… After only a few weeks, the over prominence in my brow area and muscle bulk has already substantially reduced, which I have not had with my previous treatments. Without a doubt, ARCHITOX™ will benefit every person within my demographic considering Botox. My only regret was not discovering this company sooner and wasting time and money with other injectors not using the ARCHITOX™ technique.”
Provider Story
Elyse Poulin NP - Owner of Brain & Body Co, Toronto CA
“I reached out to Megan to gain insight into how I could apply her signature ARCHITOX™ method that utilizes high-dose Botox and a tailored injection pattern… I adapted Megan’s technique and have notably benefited from it - not only with increased client satisfaction, but also… my confidence as a Nurse Practitioner in the medical aesthetics field was immediately heightened.”
Behind the
Method
Injecting since 2013, Megan is a 5-time featured expert recognized for her full-face transformations. As the Founder of POUTx, she developed ARCHITOX™, an advanced high-dose Botox application method, along with the FierceFACEformula™ and HydratedNOTinflated™ Lip method.
With a vision of elevating the injectable industry through data-driven aesthetics, Megan built and leads a team of ArchiTECHS™—injectors trained in her specialized methodology—who have collectively propelled POUTx into a top-ten provider of Botox in Ontario. Together, they’ve created raving fans, earning over 600+ 5-star Google reviews and setting a new standard for injectable applications.
A recognized speaker at the Canadian Board of Aesthetic Medicine Congress, Megan has also been invited to speak internationally. She has contributed to the Allergan advisory panel, sharing her findings on high-dose Botox, and remains committed to shaping the future of injectables by mentoring providers eager to elevate their clinical expertise.
Founder/Face Maker/Innovator Megan Kozak RN